Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada

INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.

Saved in:
Bibliographic Details
Main Authors: Amir A Tahami Monfared, Amy K O’Sullivan, Coleman Rotstein, George Papadopoulos
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2012/583630
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849308359623180288
author Amir A Tahami Monfared
Amy K O’Sullivan
Coleman Rotstein
George Papadopoulos
author_facet Amir A Tahami Monfared
Amy K O’Sullivan
Coleman Rotstein
George Papadopoulos
author_sort Amir A Tahami Monfared
collection DOAJ
description INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.
format Article
id doaj-art-0f4e49d9cb5147faa4328000452e848b
institution Kabale University
issn 1712-9532
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-0f4e49d9cb5147faa4328000452e848b2025-08-20T03:54:29ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322012-01-01232596410.1155/2012/583630Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in CanadaAmir A Tahami Monfared0Amy K O’Sullivan1Coleman Rotstein2George Papadopoulos3Merck & Co Inc, Kirkland, Quebec, Canadai3 Innovus, Medford, Massachusetts, USAUniversity of Toronto, University Health Network, Toronto, Ontario, CanadaMerck & Co Inc, Whitehouse Station, New Jersey, USAINTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.http://dx.doi.org/10.1155/2012/583630
spellingShingle Amir A Tahami Monfared
Amy K O’Sullivan
Coleman Rotstein
George Papadopoulos
Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
Canadian Journal of Infectious Diseases and Medical Microbiology
title Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
title_full Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
title_fullStr Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
title_full_unstemmed Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
title_short Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada
title_sort economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in canada
url http://dx.doi.org/10.1155/2012/583630
work_keys_str_mv AT amiratahamimonfared economicevaluationofposaconazoleversusstandardazoletherapyasprophylaxisagainstinvasivefungalinfectionsinpatientswithprolongedneutropeniaincanada
AT amykosullivan economicevaluationofposaconazoleversusstandardazoletherapyasprophylaxisagainstinvasivefungalinfectionsinpatientswithprolongedneutropeniaincanada
AT colemanrotstein economicevaluationofposaconazoleversusstandardazoletherapyasprophylaxisagainstinvasivefungalinfectionsinpatientswithprolongedneutropeniaincanada
AT georgepapadopoulos economicevaluationofposaconazoleversusstandardazoletherapyasprophylaxisagainstinvasivefungalinfectionsinpatientswithprolongedneutropeniaincanada